Objective: The aim of this study was to perform economic evaluation and network Meta-analysis of three Chinese herb injections combined with NP chemotherapy for non-small cell lung cancer (NSCLC). Method: CNKI

CBM and Wanfang Databases were searched to include clinical trials about Chinese herb injections combined with NP chemotherapy for elderly NSCLC. Two evaluators independently selected the trials

performed the data extraction and evaluated the quality of included studies. Network Meta-analysis and pharmacoeconomics analysis were conducted. Result: A total of 14 randomized clinical trials (RCTs) involving 1 118 patients were included. Kanglaite injection+NP chemotherapy ranked first and had the highest probability in the outcome of near-term curative effect (71%). Shenqi Fuzheng injection+NP chemotherapy ranked first and had the highest probability in the outcome of quality of life (56%). The economic evaluation showed that

the cost-effectiveness ratios and incremental cost-effectiveness ratio of four therapy strategies were as follows:Aidi injection+NP 425.88/425.88 yuan

Kanglaite injection+NP 385.23/213.05 yuan

Shenqi Fuzheng injection+NP 389.77/118.97 yuan

and NP chemotherapy 477.18/0 yuan

respectively. Conclusion: Shenqi Fuzheng injection+NP chemotherapy is considered as an optimum treatment. But we need more strictly-designed and RCTs of large-scale sample to support our conclusion.